Vulvar and vaginal squamous cell carcinoma · line 1 · Pembrolizumab monotherapy
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-PEMBROLIZUMAB-MONO |
| ID | IND-VULVAR-VAGINAL-SCC-METASTATIC-1L-PEMBRO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-VULVAR-VAGINAL-SCC |
| Sources | SRC-KEYNOTE-158-VULVAR-SHAPIRA-FROMMER-2022 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted per CHARTER §8.3 — draft content only, NOT published/verified clinical advice). KEYNOTE-158 vulvar cohort enrolled PREVIOUSLY TREATED advanced disease (typically post-platinum or post-chemoradiation), not treatment-naive metastatic disease — this Indication is nonetheless positioned as the metastatic '1L systemic' option in ALGO-VULVAR-VAGINAL-SCC-1L per this authoring pass's scope, because no platinum-based cytotoxic chemotherapy Indication is yet authored for metastatic vulvar/vaginal SCC (open gap). PD-L1 CPS gating is a cross-tumor convention applied here for consistency with other pembrolizumab Indications in this KB, NOT a vulvar-SCC-validated cutoff — KEYNOTE-158 vulvar cohort responses occurred regardless of PD-L1 status (see RF-VULVAR-VAGINAL-SCC-PDL1-CPS-1-PLUS notes). Reuses REG-PEMBROLIZUMAB-MONO and DRUG-PEMBROLIZUMAB entirely unchanged — no existing file was modified.
Used By
Algorithms
ALGO-VULVAR-VAGINAL-SCC-1L- ALGO-VULVAR-VAGINAL-SCC-1L
Disease
DIS-VULVAR-VAGINAL-SCC- Vulvar and vaginal squamous cell carcinoma